

Antihemorrhagic agent. It is a synthetic analogue of vitamin K. It is a cofactor for the synthesis of prothrombin and other blood coagulation factors (VII, IX, X) in the liver, contributes to the normalization of the blood coagulation process.
Hemorrhagic syndrome associated with hypoprothrombinemia; hypovitaminosis K (including with obstructive jaundice, hepatitis, cirrhosis of the liver, prolonged diarrhea); hemorrhagic disease of the newborn; bleeding after injuries, injuries and surgical interventions; in gynecology as part of complex treatment of dysfunctional uterine bleeding, not associated with organic pathology, in menorrhagia. As a specific antagonist in bleeding associated with the administration of indirect anticoagulants. III trimester of pregnancy (to prevent bleeding in newborns).
1 ampoule (1 ml) contains 10 mg of menadione sodium bisulfite
Menadione sodium bisulfite is marketed under different brands and generic names, and comes in different dosage forms:
Brand name | Manufacturer | Country | Dosage form |
---|---|---|---|
Vicasol | Dalkhimpharm | Russia | ampoules |
Vicasol | Pharmstandard | Russia | pills |
Vicasol | Ellara | Russia | ampoules |
No customer reviews for the moment.
Vicasol prescribed by mouth for 15-30 mg per day for adults.
Children under the age of 1 year - 2-5 mg per day, from 1 to 2 years old - 6 mg per day, 3-4 years - 8 mg per day, 5-9 years - 10 mg per day, 10- 14 years - 15 mg per day. Reception frequency - 2-3 times a day.
The maximum daily dose of the drug for newborns - 4 mg.
Duration of treatment is 3-4 days. The course of treatment is repeated after 4 days break.
Carefully:
Reduces or blocks the anticoagulant action of neodicoumarin and fenilina. Does not affect the anticoagulant activity of heparin. Simultaneous administration with broad-spectrum antibiotics, quinidine, quinine, high-dose salicylates, antibacterial sulfonamides requires an increase in the dose of vitamin K.
It is used during pregnancy according to indications.
In hemophilia, von Willebrand and Verlhof disease, the drug is ineffective.
When glucose-6-phosphate dehydrogenase is deficient, it can cause hemolysis.
Rarely - hypervitaminosis K, manifested hyperprothrombin- and hyperthrombinemia, hyperbilirubinemia, increased blood clotting, thromboembolism. Symptomatic treatment.